Gilead Shot Provides Full Protection From HIV in Study of Young African Women
More news - News 24 hours
It can take years for generic drugmakers to be ready to produce a drug, and they need to have a sense of the potential market to commit to investing in production. So in the meantime, Gilead will aim to ship "sufficient volumes" of lenacapavir to low-income countries as soon as it gets regulatory approval, he said.
Lenacapavir and the two pills studied are all known as pre-exposure prophylaxis drugs, or PrEP. Another effective injectable PrEP drug is available in some African countries, but its introduction has been plagued by access issues. Long-acting cabotegravir, which is injected every two months, has also shown excellent results in clinical trials in Africa. It is made by ViiV Healthcare, majority-owned by pharmaceutical giant GSK; the company c...